Seroconversion of a trivalent measles, mumps, and rubella vaccine in children aged 9 and 15 months

Forleo‐Neto, Eduardo; Carvalho, Eduardo S.; Fuentes, Isabel C.P.; Precivale, Maristela S.; Forleo, Luiza H.A.; Farhat, Calil Kairalla

doi:10.1016/s0264-410x(97)00135-7

Cited by 15 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our finding confirms the results reported in other studies of children aged 10-24 months [32,33]. In Brazil, Forleo-Neto et al [16] demonstrated 100% seroconversion ∼6 weeks after a single dose of trivalent measlesmumps-rubella (MMR) vaccine in 15-month-old children. In India, Singh et al [34] found that rubella IgG seroconversion occurred in 94% of children given a dose of MMR vaccine at age 12 or 15 months.…”

Section: Discussionsupporting

confidence: 92%

“…Unlike several previous studies that reported lower measles vaccine immunogenicity (∼85%) in developing countries [11][12][13][14], we found high seroconversion rates consistently in four different areas of Oman. Although these rates were higher than expected on the basis of other studies [15][16][17][18], several studies using Schwarz measles vaccine at 9 months of age have shown high seroconversion at different time intervals after vaccination. One recent study showed high seroconversion (98.8%) 30 days after measles vaccination in 9-month-old Indonesian infants [19]; similarly, rates of seroconversion among 400 children in Cô te d'Ivoire receiving Schwarz vaccine at 9 months were 98.1% 5 weeks after vaccination [20].…”

Section: Discussioncontrasting

confidence: 70%

See 1 more Smart Citation

Immunogenicity of Measles and Rubella Vaccines in Oman: A Prospective Clinical Trial

Kohler¹,

Suleiman²,

Robertson³

et al. 2003

J INFECT DIS

View full text Add to dashboard Cite

A prospective immunogenicity trial of measles and rubella vaccines was conducted in Oman. Children received measles vaccine at age 9 months and measles-rubella vaccine at age 15 months. Serum specimens were tested for measles-specific IgG and rubella-specific IgG. Of 1025 eligible infants, 881 (86.0%) returned for all five visits and had adequate serum samples for testing. Seroconversion to measles after vaccination at 9 months was 98.1%. At 15 months, 47 (5.3%) of the 881 children were seronegative for measles; of these, 44 (93.6%) seroconverted. At 16 months, 99% of the children seronegative at age 9 months seroconverted after receiving two doses of measles vaccine. At age 15 months, 684 (77.6%) children were seronegative for rubella. Of these, 676 (98.8%) seroconverted by age 16 months. One dose of measles vaccine at age 9 months was highly immunogenic. One dose of measles-rubella vaccine at age 15 months closed the remaining measles immunogenicity gap and resulted in a high rate of rubella seroconversion.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussioncontrasting

confidence: 70%

Immunogenicity of Measles and Rubella Vaccines in Oman: A Prospective Clinical Trial

Kohler¹,

Suleiman²,

Robertson³

et al. 2003

J INFECT DIS

View full text Add to dashboard Cite

show abstract

“…However, later birth year was not associated with improved response to mumps vaccine (analyses not shown). Several studies have examined the effect of age at vaccination on response to the Urabe strain of mumps vaccine [18][19][20]; 1 study found a reduction in seroconversion rate [19] and 2 did not [20,21]. No data are available on the Jeryl Lynn strain of mumps vaccine used in the United States.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Vaccination with Measles-Mumps-Rubella Vaccine at 9, 12, and 15 Months of Age

Redd

King

Heath

et al. 2004

The Journal of Infectious Diseases

View full text Add to dashboard Cite

To determine seroconversion rates with measles-mumps-rubella vaccine administered to children at 9, 12, or 15 months of age, we undertook a prospective randomized trial. Among children vaccinated at 15 months of age, 98% seroconverted to measles, compared with 95% of those vaccinated at 12 months of age and 87% of those vaccinated at 9 months of age. In each age group, children of mothers born in or before 1963 had lower rates of seroconversion against measles, with the lowest rate in children vaccinated at 9 months. The seroconversion rate of rubella paralleled that of measles, with the lowest seroconversion rates in children vaccinated at 9 months of age whose mothers were born in or before 1963. The response to mumps varied little by age of the child or birth year of the child's mother. These results support the recommended age for first vaccination with measles-mumps-rubella at 12-15 months.

show abstract

“…82, 83 The high seroconversion rate of 99% is observed as early as 9-months-old after receiving the Wistar RA 27/3 live rubella virus vaccine strain. 84 With a calculated half-life of 114 years, rubella-specific antibodies may even persist for an entire lifetime. 85 Although excellent seroconversion rates are obtained with RA27/3 vaccination, there are limited occurrences of vaccine failure, and this is thought to arise when preexisting antibodies neutralize the live viral vaccine strain.…”

Section: Rubella Vaccine Immunogeneticsmentioning

confidence: 99%

Rubella

et al. 2015

View full text Add to dashboard Cite

Rubella remains an important pathogen globally with approximately 100,000 cases of congenital rubella syndrome estimated to occur each year. Rubella vaccine is highly effective and safe when used across a population and, as a result, endemic rubella transmission has been interrupted in the Americas since 2009. Incomplete rubella vaccination programs result in continued disease transmission as evidenced by recent large outbreaks in Japan and elsewhere. Herein, we provide current results regarding rubella control, elimination and eradication policies, and a brief review of new laboratory diagnostics. In addition, we provide novel information regarding rubella vaccine immunogenetics and review the emerging evidence of inter-individual variability in humoral and cell-mediated innate and adaptive immune responses to rubella vaccine and their association with HLA alleles, haplotypes, and single nucleotide polymorphisms across the human genome. Finally, we conclude with a call for further research in rubella vaccine immunogenetics and its ability to inform a vaccinomics-level approach to novel vaccine candidate development and the need for a next generation vaccine that is affordable, easy to administer, and does not require a cold chain for optimal immunogenicity.

show abstract

Seroconversion of a trivalent measles, mumps, and rubella vaccine in children aged 9 and 15 months

Cited by 15 publications

References 18 publications

Immunogenicity of Measles and Rubella Vaccines in Oman: A Prospective Clinical Trial

Immunogenicity of Measles and Rubella Vaccines in Oman: A Prospective Clinical Trial

Comparison of Vaccination with Measles-Mumps-Rubella Vaccine at 9, 12, and 15 Months of Age

Rubella

Contact Info

Product

Resources

About